|
Video: What is a Stock Split?
|
|
Sierra Oncology is a late-stage biopharmaceutical company focused on therapies that treat cancer. Co.'s focus is the development and commercialization of momelotinib, an investigational agent for the treatment of myelofibrosis. Momelotinib is a small-molecule inhibitor of JAK1 (Janus kinase 1), JAK2 (Janus kinase 2) and ACVR1 (Activin A receptor type 1), under development for treatment of patients with myelofibrosis. Co. has conducted a review of data from the two Phase 3 trials of momelotinib, versus ruxolitinib and best available therapy, as well as GS-US-352-1672, a Phase 2, open-label, translational biology trial of momelotinib in transfusion-dependent subjects with myelofibrosis. According to our SRRA split history records, SRRA has had 1 split. | |
|
SRRA (SRRA) has 1 split in our SRRA split history database. The split for SRRA took place on January 23, 2020. This was a 1 for 40 reverse split, meaning for each 40 shares of SRRA owned pre-split, the shareholder now owned 1 share. For example, a 1000 share position pre-split, became a 25 share position following the split.
When a company such as SRRA conducts a reverse share split, it is usually because shares have fallen to a lower per-share pricepoint than the company would like. This can be important because, for example, certain types of mutual funds might have a limit governing which stocks they may buy, based upon per-share price. The $5 and $10 pricepoints tend to be important in this regard. Stock exchanges also tend to look at per-share price, setting a lower limit for listing eligibility. So when a company does a reverse split, it is looking mathematically at the market capitalization before and after the reverse split takes place, and concluding that if the market capitilization remains stable, the reduced share count should result in a higher price per share.
Looking at the SRRA split history from start to finish, an original position size of 1000 shares would have turned into 25 today. Below, we examine the compound annual growth rate — CAGR for short — of an investment into SRRA shares, starting with a $10,000 purchase of SRRA, presented on a split-history-adjusted basis factoring in the complete SRRA split history.
Growth of $10,000.00
Without Dividends Reinvested
|
Start date: |
01/11/2017 |
|
End date: |
07/01/2022 |
|
Start price/share: |
$56.80 |
|
End price/share: |
$54.99 |
|
Dividends collected/share: |
$0.00 |
|
Total return: |
-3.19% |
|
Average Annual Total Return: |
-0.59% |
|
Starting investment: |
$10,000.00 |
|
Ending investment: |
$9,681.58 |
|
Years: |
5.47 |
|
|
|
Date |
Ratio |
01/23/2020 | 1 for 40 |
|
|